NasdaqGS:RIGLBiotechs
Rigel Pharmaceuticals (RIGL) Is Down 7.7% After Issuing Detailed 2026 Revenue Mix Guidance – Has The Bull Case Changed?
In January 2026, Rigel Pharmaceuticals issued full-year 2026 earnings guidance, projecting total revenue of about US$275 million to US$290 million, including US$255 million to US$265 million in net product sales and US$20 million to US$25 million in contract revenue.
This fresh guidance gives investors a clearer view of how management currently sees the balance between core product sales and partnership-driven contract income.
We’ll now consider how Rigel’s new 2026 revenue guidance,...